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Abstract
Background. Drug trials often exclude subjects with rele-
vant comorbidity or comedication. Nevertheless, after ap-
proval, these drugs will be prescribed to a much broader
collective. Our goal was to quantify the impact of drugs
and comorbidity on serum potassium in unselected patients
admitted to the hospital.
Methods.This was a retrospective pharmacoepidemiologic
study in 15 000 consecutive patients admitted to the med-
ical department of the Kantonsspital St. Gallen, a 700-
bed tertiary hospital in eastern Switzerland. Patients with
‘haemolytic’ plasma and patients on dialysis or with an es-
timated glomerular filtration rate (GFR)<10 mL/min/1.73
m2 were excluded. For the remaining 14 146 patients, drug
history on admission, age, sex, body weight, physical find-
ings, comorbidity (ICD-10 diagnoses) and laboratory in-
formation (potassium and creatinine) were extracted from
electronic sources.
Results. Estimated GFR was the strongest predictor
of serum potassium (P< 0.0001). Angiotensin-converting
enzyme inhibitors, cyclosporine, loop diuretics and
potassium-sparing diuretics all showed a significant effect
modification with decreasing GFR (P< 0.001). Similarly,
in patients with liver cirrhosis a significantly stronger effect
on potassium was found for angiotensin receptor blockers,
betablockers and loop diuretics (P< 0.01). Several signifi-
cant drug–drug interactions were identified. Diabetes, male
sex, older age, lower blood pressure and higher body weight
were all independently associated with higher serum potas-
sium levels (P < 0.001). The model explained 14% of the
variation of serum potassium.
Conclusions. The effects of various drugs on serum potas-
sium are highly influenced by comorbidity and comedi-
cation. Although the presented model cannot be used to
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predict potassium in individual patients, we demonstrate
that clinical databases could evolve as a powerful tool
for industry-independent analysis of postmarketing drug
safety.
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Introduction
Potassium is the most abundant cation in the body. The vast
majority (98%) of total body potassium (4000 mmol) is
stored in the intracellular fluid compartment, whereas only
about 60 mmol are in the extracellular fluid [1,2]. Total
body potassium contents are balanced by food intake and
urinary and faecal losses. The two main regulators of renal
potassium excretion are mineralocorticoid activity and the
availability of sodium in the distal nephron [3]. In healthy
people, serum potassium is further maintained in a narrow
range by key hormones (insulin, β-adrenergic agonists),
promoting its entry into the cells via Na+/K+-ATPase [2].
Both hypokalaemia and hyperkalaemia are associated with
increased mortality, mainly due to a higher risk of poten-
tially fatal arrhythmia [2,4,5].
Several clinical conditions are associated with either in-
creased (e.g. renal dysfunction, hypoaldosteronism) or de-
creased (e.g. diarrhoea, hyperaldosteronism) serum potas-
sium concentration [5,6].Many frequently prescribed drugs
influence the serumpotassium concentration by eithermod-
ulating renal potassium excretion (e.g. diuretics) or by tran-
scellular shifting (e.g. insulin and β-mimetics) [1,6]. The
magnitude of these drug-induced changes and the effect
modification by disease is often unknown, since patients
with relevant comorbidity tend to be excluded from drug
trials. We therefore aimed to determine the relative contri-
butions of drugs and comorbidities on serum potassium in
a large, unselected cohort of patients admitted to a repre-
sentative tertiary referral centre.
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Methods
Patients
The Kantonsspital St. Gallen is the main tertiary refer-
ral centre in eastern Switzerland. Fifteen thousand con-
secutive patients admitted to the Department of Internal
Medicine between January 2002 and July 2004 were in-
cluded in this study. Patients on dialysis and those with
an estimated glomerular filtration rate (GFR)<10 mL/min
were excluded. If the first blood sample was ‘haemolytic’,
the patient was also excluded, unless a non-haemolytic
sample was available within 24 h of admission. Com-
plete drug history on admission, age, sex, body weight,
blood pressure and comorbidities (ICD-10-diagnoses: con-
gestive heart failure, liver cirrhosis, diabetes, diarrhoea,
vomiting and malabsorption) were derived from the elec-
tronic patient record (Phoenix c©, Parametrix, Lachen,
Switzerland).
Drug history and defined daily doses
Seventeen drugs or groups of drugswith either a potassium-
lowering or a potassium-increasing potential were recorded:
angiotensin-converting enzyme inhibitors (ACEIs; 12 dif-
ferent generic substances), angiotensin receptor blockers
(ARBs; 4), betablockers (14), β2-mimetics (5), carboan-
hydrase inhibitors (1), corticosteroids (5), calcineurin in-
hibitors (2), digitalis (1), L-Dopa or dopamine agonists
(4), high- and low-molecular-weight heparin (4), laxa-
tives (>10), loop diuretics (2), nonsteroidal antiinflam-
matory drugs (NSAID; 18), K-sparing diuretics (3), theo-
phylline (1), potassium supplements, as well as thiazides
(6). Insulin and other antidiabetics were not included in
the analysis because they were considered substitutes for
an endogenous hormone deficiency and at the same time
highly collinear with the variable diabetes, which was in-
cluded in the analysis. To standardise doses of differ-
ent drugs within a class, the daily dose of a given sub-
stance was expressed as multiples of a defined daily
dose (DDD) according to the world health organization
(WHO) [7].
Laboratory analysis
Creatinine and potassium values were extracted from the
laboratory database. GFR was estimated according the
modification of diet in renal disease (MDRD)-short for-
mula (186 × (SCr) exp −1.154 × (age) exp −0.203 ×
0.742 (if the subject is female) [8]. Correction for African
background was not done because this information was
not available and <1% of the local population is black.
GFR was tested as a linear predictor and after log trans-
formation. Log-transformed GFR proved to be the stronger
predictor. For the graphical display of the results patients
were stratified according to the National Kidney Founda-
tion (NKF) classification: (i) GFR ≥90 mL/min, (ii) GFR
60–89 mL/min, (iii) GFR 30–59 mL/min, (iv) GFR 15–
29 mL/min and (v) GFR <15 mL/min [8].
Statistical analysis
Statistical analysis was performed using SAS release 8.2
(SAS institute Inc., Cary, NC, USA). Continuous variables
are presented as means and standard deviations (SD), or
as medians and interquartile range (IQR), and categorical
variables as percentages (%) and rates. Missing values for
body weight were imputed using a regression model with
the variables gender and age. If the strength of the drug
or the exact dosing schedule was not reported or ambigu-
ous, the daily intake of 1 DDD was assumed. If the drug
was taken ‘on demand’ the daily intake of half DDD was
assumed.
A mixed-effects regression model, controlled for clus-
tering by repeated admission of individual patients was
developed. All variables were included in the model, irre-
spective of their statistical significance. Predefined inter-
actions were identified using backward elimination tech-
niques and they were only included in the final model if
their P-value was <0.05. Predictors of low (<3.0 mmol/L)
and high (>5.0 mmol/L) potassium were identified using
logistic regression and backward elimination techniques.
These models were not adjusted for clustering.
Results
From the original cohort of 15 000 admissions, 283 were
excluded due to dialysis or GFR<10mL/min, and 571were
excluded due to ‘haemolytic’ plasma. The present analysis
is based on the data of 14 146 admissions in 10 320 pa-
tients, 4440 (43%) were females and 5880 (57%) males.
The mean (SD) age was 63.1 (16.1) years, and the weight
was 70.0 (15.6) kg. GFR was overall 77 (30) mL/min/
1.73 m2 and serum potassium (K) 3.96 (0.53) mmol/L.
Potassium increased from an average of 3.8 (0.4) mmol/L
in stage I (normal) kidney function to 4.6 (1.0) mmol/Lin
patients with stage V kidney dysfunction.
The reasons for hospital admission and the prevalence
of comorbidities are summarized in Table 1. If kidney dys-
function is omitted, overall 2829 (20%) had at least one co-
morbidity with alleged influence on serum potassium. The
most prevalent condition was diabetes (13.4%), followed by
congestive heart failure (CHF; 10.7%). The intake of drug
classes is presented in Table 2. At least one drug with the
potential to modify potassium was taken by 8909 (63%).
Betablockers were taken by almost 30%; the second largest
group were inhibitors of the renin–angiotensin–aldosterone
(RAA) system, followed by various diuretics.
Predictors of excessively low or high potassium levels
In 210 patients (1.5%) K was <3.0 mmol/L, and in
520 patients (3.7%) K was >5.0 mmol/L. Diarrhoea
was the strongest predictor of K <3.0 mmol/L, followed
by anorexia/malabsorption. The potential of thiazide di-
uretics to induce hypokalaemia [Odds ratio (OR) 2.1,
P < 0.0001] was much higher than that of loop diuretics
(OR 1.05, P = 0.2). But also liver cirrhosis, lower weight
and, surprisingly, female gender were independent predic-
tors of hypokalaemia (Table 3).
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Table 1. Principal diagnoses and comorbidity at admission
N %
Principal diagnoses
Cardiovascular diseases 5248 37.1
Oncological diseases 3296 23.3
Gastrointestinal diseases 1062 7.5
Respiratory diseases 849 6.0
Neurologic/psychiatric 721 5.1
Various disorders 2970 21.0
Comorbidity
GFR ≤ 15 mL/min/1.73 m2 179 1.3
GFR 15–29 mL/min/1.73 m2 545 3.9
GFR 30–59 mL/min/1.73 m2 3203 22.6
GFR 60–89 mL/min/1.73 m2 6105 43.2
GFR ≥ 90 mL/min/1.73 m2 4114 29.1
Diabetes 1891 13.4
Congestive heart failure 1511 10.7
Diarrhoea 544 3.9
Gastrointestinal bleeding 381 2.7
Liver cirrhosis 269 1.9
Anorexia or malabsorption 60 0.4
GFR: glomerular filtration rate estimated according to the abbreviated
Modification in Diet in Renal Disease (MDRD) study formula.
Table 2. Drug use at admission
Drugs N % Daily dose
(median; IQR)
ACE-inhibitors 2538 17.9 1.0 (1.0–2.0)
Angiotensin receptor blockers 974 6.9 1.0 (1.0–2.0)
Potassium-sparing diuretics 1000 7.1 0.5 (0.3–0.7)
Loop diuretics 2291 16.2 1.0 (0.5–1.3)
Thiazide diuretics 1168 8.3 0.5 (0.5–1.0)
Carboanhydrase inhibitors 35 0.3 0.3 (0.3–0.7)
Betablockers 4210 29.8 0.5 (0.3–0.7)
Betaadrenergic stimulants 852 6.0 0.8 (0.8–1.1)
Dopaminergic drugs 160 1.1 0.6 (0.3–1.0)
Theophylline 62 0.4 1.0 (0.8–1.0)
Corticosteroids 922 6.5 1.0 (0.5–2.5)
Heparinoids 925 6.5 2.0 (1.5–3.0)
Cyclosporine 167 1.0 0.8 (0.4–1.1)
Nonsteroidal
anti-inflammatory drugs
796 5.6 0.5 (0.3–1.3)
Digitalis 445 3.2 0.5 (0.5–1.0)
Laxatives 944 6.7 2.0 (1.0–4.0)
Potassium supplements 134 1.0 1.0 (0.7–2.0)
N: number of persons affected; Daily dose: cumulative daily dose ex-
pressed as multiples of defined daily dose (DDD) according to WHO;
IQR: interquartile range; ACE: angiotensin-converting enzyme.
The strongest predictor of K>5.0 mmol/L was the com-
bination of ACE inhibitors with K-sparing diuretics (OR
4.0; P < 0.0001). K-sparing diuretics alone, cyclosporine,
ACE inhibitors and ARBs were also associated with hy-
perkalaemia. ARBs had an identical OR of 1.2 per DDD
as ACE inhibitors, but due to a smaller sample size (only
974 patients took ARBs as opposed to 2538 patients taking
ACE inhibitors) the former association was not statistically
significant (P = 0.11). Among non-pharmaceutical influ-
ences, impaired kidney function, diabetes and higher body
weight were all significantly associatedwith hyperkalaemia
(Table 3).
Table 3. Predictors of extreme potassium values
Potassium <3.0 mmol/L OR 95% CI P value
Diarrhoea 4.0 2.9–5.5 <0.0001
Malabsorption or anorexia 3.6 1.6–8.3 <0.01
Thiazide diuretics 3.5 2.6–4.7 <0.0001
Cirrhosis 2.7 1.5–5.0 0.0008
Female gender 1.6 1.3–2.0 <0.0001
Weight (per 10 kg lower) 1.2 0.7–0.9 <0.0001
Loop diuretics 1.1 1.0–1.2 0.06
Potassium >5.0 mmol/L
ACE inhibitors in combination
with potassium-sparing diuretics
4.0 2.7–5.9 <0.01
GFR (per 10 mL/min/1.73 m2
lower)
2.0 1.9–2.1 <0.0001
Potassium sparing diuretics 1.9 1.4–2.7 <0.0001
Diabetes 1.7 1.3–2.2 <0.0001
Cyclosporine 1.4 1.1–1.7 <0.001
Weight (per 10 kg higher) 1.3 1.2–1.4 <0.0001
ACE inhibitors 1.2 1.02–1.4 0.02
AT2-receptor blockers 1.2 0.9–1.5 0.1
Adjusted for risk factors and drugs with alleged influence on potassium.
OR: odds ratio per one defined daily dose (DDD); 95% CI: lower and
upper 95% confidence intervals; ACE: angiotensin-converting enzyme;
AT2-receptor: angiotensin receptor 2 blocker.
Regression model
Renal function evolved as the strongest predictor of serum
potassium (P< 0.0001). Log GFR proved to be a bet-
ter predictor than GFR. Older persons with similar GFR
had slightly higher potassium values than younger per-
sons (±0.01 mmol/L per decade; P< 0.001). Male sex was
associated with higher serum potassium (±0.16 mmol/L;
P< 0.0001). A negative association between blood pressure
and potassium was further evident (P< 0.001).
Diabetes was associated with significantly higher potas-
sium even after adjustment for bodyweight (P< 0.0001). A
mild elevation of potassium in the presence of CHF or liver
cirrhosis in the univariate analysis was no longer present
after multivariate adjustment; however, a strong potassium-
lowering effect could be attributed to vomiting and diar-
rhoea (P< 0.0001) (Figure 1). The effect of ACE inhibitors,
and K-sparing diuretics on serum potassium was ampli-
fied with decreasing renal function (P< 0.001), whereas
the potassium-lowering effect of loop-diuretics decreased
with lower estimated GFR (P< 0.0001). Similarly, liver
cirrhosis significantly enhanced the effect of ARBs and
loop diuretics on serum potassium (P< 0.01). Likewise,
the potassium-lowering effect of thiazide diuretics was di-
minished in CHF (Figure 2).
For ACE inhibitors (P< 0.0001), cyclosporine (P<
0.0001), K-sparing diuretics (P< 0.0001) and surprisingly
also inhalative beta stimulants (P = 0.04) and laxatives
(P< 0.0001) a significant association with higher serum
potassium was found, whereas the intake of loop diuretics
(P< 0.01) and thiazides (P< 0.0001) was associated with
lower values. For several drugs no significant association
between dose and serum potassium could be proven in this
multivariate analysis (ARBs, betablockers, carboanhydrase
inhibitors, digitalis, heparin, NSAIDs, corticosteroids and
theophylline). We believe that—despite the relatively large
sample size—this is mainly due to limited power. In the
case of heparin, the exposure to the drug may have been
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Fig. 1. Effect of patient characteristics and comorbidity on serum potassium. Vertical axis: serum potassium concentration in mmol/l. CHF denotes
congestive heart failure. Error bars: 95% confidence limits.
too short, since most persons with heparin were transferred
from regional hospitals due to acute coronary syndromes.
Nevertheless, the model undoubtedly has to be adjusted
for the well-known effects of these compounds. Moreover,
many of the latter drugs had significant interactions with
other drugs or comorbidity.
Significant additive drug–drug interactions were found
for ACE inhibitors with K-sparing diuretics and for
betablockers with NSAIDs, whereas the potassium-
lowering effect of thiazide diuretics was significantly re-
duced by ACE inhibitors, NSAIDs and K-sparing diuretics.
SimilarlyARBs attenuated the potassium-lowering effect of
loop diuretics. The R2, i.e. the explained variance of serum
potassium by the regression model, amounted to 0.14.
Discussion
We have shown that in an unselected population admitted
to a representative tertiary referral centre, several drugs as
well as comorbidities and demographic factors have a sig-
nificant impact on serumpotassium. In addition, the present
analysis demonstrates that the potassium-modifying effects
of several classes of drugs are altered by renal or hepatic
dysfunction. The majority of the identified relationships
are in line with the knowledge about pharmacokinetics and
pharmacodynamics of the tested drugs, whereas some of
them are unexpected, warrant further explanation, or high-
light some limitations of our study.
Renal function
As anticipated, we identified a strong inverse relation be-
tween GFR and serum potassium. Several mechanisms im-
pair the excretion of potassium with decreasing renal func-
tion: (i) decreased delivery of sodium to the distal nephron,
(ii) aldosterone deficiency and (iii) abnormal function of the
cortical collecting ducts [3]. In addition, hyporeninaemic
hypoaldosteronism and metabolic acidosis may contribute
to hyperkalaemia. Renal dysfunction additionally enhanced
the potassium-retaining effect of cyclosporine and of some
inhibitors of the RAA system (see below).
Liver cirrhosis, CHF and blood pressure
Both liver cirrhosis and CHF are commonly associated with
secondary hyperaldosteronism [9]. Nevertheless, neither in
cirrhosis nor in CHF was a significant reduction of serum
potassium found in our adjusted model. This may be at-
tributed to renal sodium sparing. Effective kaliuresis in
hyperaldosteronism is only possible if sufficient sodium
reaches the distal renal tubule. Intravascular volume de-
pletion (in cirrhosis) with consecutive hyponatraemia due
to non-osmotic vasopressin secretion may limit natriure-
sis and thereby kaliuresis. Indeed, serum sodium concen-
tration was on average 4 mmol/L lower (P< 0.0001) in
patients with liver cirrhosis than in other patients. Cirrho-
sis further resulted in a significant amplification of the
potassium-modifying effects of ARBs and loop diuretics.
This may be explained by potent natriuresis in the case of
loop diuretics [10] or an antagonism of hyperaldosteronism
(ARBs).
The potassium-lowering effect of thiazide diuretics was
mitigated in patients with CHF. This may be attributed to
the fact that hypotension reduces the glomerular filtration
of sodium and thus kaliuresis [11]. This concept of pressure
natriuresis is supported by a significant inverse relationship
between blood pressure and serum potassium in our data.
However, also an inverse causal association may be true:
low potassium intake (with a consecutive deficit of potas-
sium in the body) has been accused of causing hypertension
[12].
Inhibitors of the renin–angiotensin–aldosterone system
In patients with CHF, clinical trials have shown a survival
benefit for ACE inhibitors and ARBs either alone [13,14]
or in combination [15,16]. Interestingly, the rate of hyper-
kalaemia was very low in these major trials, whereas in
unselected outpatients 10% develop hyperkalaemia during
1 year of therapy [17]. We found a strong dose–effect rela-
tionship between therapywith ACEIs and serum potassium.
Due to an interaction with kidney function, this effect was
most pronounced in patients with lower GFR. The effect of
ARBs seemed to be much milder and no interaction with
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Fig. 2. Effect of drugs on serum potassium. Vertical axis: serum potassium concentration in mmol/l. Horizontal axis: DDD (defined daily dose of a
drug class according to WHO definitions). All drug effects are normalized for a 50-year-old male patient with a GFR of 50 ml/min/1.73 m2 and a body
weight of 75 kg. GFR stands for estimated glomerular filtration rate. ∗A significant interaction between drug and estimated GFR.
kidney function was found for ARBs, which is consistent
with earlier trials [18–20]. One explanation for this differ-
ence may be that many ACE inhibitors accumulate in renal
failure, whereas ARBs are usually eliminated by the liver.
Potassium-sparing diuretics
The intake of K-sparing diuretics was strongly predictive
of higher serum potassium, and the magnitude of this ef-
fect increased with declining renal function. Spironolac-
tone has been shown to provide additional cardiovascu-
lar protection in patients with CHF, maximal therapy and
NYHA classes III–IV [21]. The rate of hyperkalaemia in
the key study [21] was extremely low (1%), probably due
to careful selection [average serum creatinine level was
1.2 mg/dL (106 µmol/L)] and rigorous monitoring of the
participating patients. However, there is substantial evi-
dence that the incidence of hyperkalaemia is much higher,
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if patients with more advanced renal failure, comorbidities
and less intense monitoring undergo the same treatment
[22,23]. This holds especially true if several drugs with an
influence on theRAA system are combined [24]. Indeed,we
found an OR of four for the development of hyperkalaemia
if ACEIs were combined with K-sparing diuretics.
Calcineurin inhibitors
Immunosuppressive therapywith calcineurin inhibitors was
strongly predictive of elevated potassium levels even after
adjustment for hyperkalaemia due to impaired kidney func-
tion. Our results are in accordance with previous studies,
which found hyperkalaemia in up to 73% of transplant re-
cipients treated with cyclosporine or tacrolimus [25]. The
mechanisms of cyclosporine-induced hyperkalaemia seem
to include renal tubular dysfunction and secondary hypoal-
dosteronism [26,27].
Non-steroidal anti-inflammatory drugs
NSAIDs reduce prostaglandin-dependent renin-release and
vasodilatation of the renal afferent arteriole. This predis-
poses to impaired kidney function and hyperkalaemia [11].
In our data, a strong tendency towards higher serum potas-
sium in patients taking NSAIDs was no longer significant
after adjustment for renal dysfunction. Therefore, the po-
tential of NSAIDs to increase potassium beyond a drug-
mediatedworsening of kidney functionmay be rather small.
Our analysis, however, suggests a significant potassium-
retaining interaction between NSAIDs and beta-blockers
as well as thiazide diuretics.
β2-mimetics
In contrast to our expectationswe found significantly higher
potassium concentrations in patients with a drug history of
inhalative β2-mimetics. These drugs induce a short-term
potassium shift into the cell, which has also been docu-
mented in several studies for their inhalative forms [28,29].
One explanation for our seemingly paradox findings may
be a partial β2-antagonistic effect of salbutamol. In a state of
increased adrenergic tone this effect has been shown to lead
to an increase of serum potassium similarly to the effect of
beta-blocking agents [30].
Laxatives
The most unexpected finding in our study was a signifi-
cantly higher serum potassium level in patients taking lax-
atives. Although hypokalaemia can be observed in laxative
abuse, no changes of serum electrolytes is usually found if
newer laxatives are taken at the recommended doses [31].
However, the use of laxatives indicates the presence of con-
stipation and patients usually do not overcorrect consti-
pation to the point of inducing diarrhoea. Stool volumes
and the consecutive electrolyte losses may thus be smaller
in constipated persons even if they report the intake of
laxatives. Furthermore constipated persons are often rec-
ommended to eat fibre-rich foods. These foods typically
contain abundant potassium, which could also explain our
seemingly paradox findings.
Hospital databases as sources of pharmacoepidemiologic
data
Our study demonstrates that hospital databases can be used
to study the effect of drugs in severely ill patients. Many of
the patients in this analysis would have been excluded from
drug studies due to comorbidity. In recent years, several
drugs had to be withdrawn from the market or their indica-
tion had to be restricted only after thousands of patients had
been exposed to them. Many tragic deaths could have been
prevented if the information of hospital databases would
systematically be analysed. Unfortunately, this information
is often little structured. We therefore propose to define
standards for the electronic documentation of medical di-
agnoses, laboratory data and drug exposure and that the
regulatory authorities should have access to the safety sig-
nals derived from the analysis of aggregated data in a timely
manner [32,33].
Limitations of the study
Our study is retrospective and the analysis is based on the
assumption that a steady state is present for all of the in-
cluded drugs and conditions at hospital admission. This as-
sumption has to be challenged because acute derangements
leading to admission, as dehydration or fever, may influence
serum electrolytes. Patients might further report to take a
prescribed drug although they were incompliant. This leads
to an underestimation of the true effect of this drug. On the
other hand some drugs may not have been reported, because
patients did not consider them to be drugs. Many drugs not
only influence the excretion of potassium, but they can also
impair kidney function (e.g. cyclosporine). If the effect of
the drug is statistically adjusted for the degree of kidney
dysfunction, which was also caused by this drug, the true
effect of the drug on potassium is again underestimated.
Finally, our model only explains 14% of the variation of
serum potassium. The residual variation may primarily be
caused by large interindividual variations of potassium in-
take with food. However, it could also be the consequence
of genetic differences in the handling of potassium, drug
metabolism and differences at the molecular site of drug
action, which have yet to be elucidated.
Conclusions
Despite these limitations several conclusions can be drawn
from the present analysis. Renal function is the strongest
single predictor of serum potassium at hospital admission.
The effects of various drugs are significantly influenced by
comedication and comorbidity. As the studied drugs and
diseases are common, our analysis adds to the understand-
ing of disturbances of serum potassium in patients with sev-
eral comorbidities and who are treated with a large number
of different drugs. Finally, our analysis demonstrates that
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hospital databases could provide cheap and reliant infor-
mation for the analysis of post-marketing drug safety.
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